Statistics

Total Visits

Views
Apremilast, an oral phosphodiesterase 4 inhibitor, is associated with long-term (52-week) improvement in measures of disease activity in patients with psoriatic arthritis: Results from 3 phase 3, randomized, controlled trials143

Select a period of time:

Number of views in the range

Views
Apremilast, an oral phosphodiesterase 4 inhibitor, is associated with long-term (52-week) improvement in measures of disease activity in patients with psoriatic arthritis: Results from 3 phase 3, randomized, controlled trials51

Views

Views
September 20252
October 20251
November 20255
December 20254
January 202617
February 20261
March 202621
Download CSV file
 untranslated
 untranslated

Top country views

Views
United States23
Brazil4
Mauritius3
Argentina2
Congo2
China2
Ecuador2
Hong Kong2
Turkey2
Venezuela2
 

Top cities views

Views
San Jose8
Ashburn4
Guayaquil2
Istanbul2
Los Angeles2
Barquisimeto2
Al Ma`adi1
Amsterdam1
Brazzaville1
Dallas1